论文部分内容阅读
辉瑞公司最近向欧洲药品监管局(EMEA)递交了阿托伐他汀(atorvastatin,Lipitor)的儿科用5mg制剂上市申请,用于治疗6～18岁家族性高胆固醇血症患者,此疾为一种罕见遗传性病症,可导致低密度脂蛋白胆固醇水平升高和心脏病风险增加。此举标志着辉瑞公司致力于延长该顶尖销售药品专利
Pfizer recently filed a pediatric 5 mg listing of atorvastatin (Lipitor) for the EMEA for the treatment of patients with familial hypercholesterolemia aged 6 to 18 years, the disease Rare genetic disorders can lead to elevated levels of low-density lipoprotein cholesterol and increased risk of heart disease. The move marks Pfizer’s commitment to extending the top-selling drug patent